24 research outputs found
Shortâ term and longâ term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota
Background and AimsAntiâ Helicobacter pylori therapy may lead to the growth of pathogenic or antibioticâ resistant bacteria in the gut. The study aimed to investigate the shortâ term and longâ term impacts of H.Ă pylori eradication with reverse hybrid therapy on the components and macrolide resistance of the gut microbiota.MethodsHelicobacter pyloriâ related gastritis patients were administered a 14â day reverse hybrid therapy. Fecal samples were collected before treatment and at the end of week 2, week 8, and week 48. The V3â V4 region of the bacterial 16S rRNA gene in fecal specimens was amplified by polymerase chain reaction and sequenced on Illumina MiSeq platform. Additionally, amplification of erm(B) gene (encoding erythromycin resistance methylase) was performed.ResultsReverse hybrid therapy resulted in decreased relative abundances of Firmicutes (from 62.0% to 30.7%; PĂ <Ă 0.001) and Actinobacteria (from 3.4% to 0.6%; 0.032) at the end of therapy. In contrast, the relative abundance of Proteobacteria increased from 10.2% to 49.1% (0.002). These microbiota alterations did not persist but returned to the initial levels at week 8 and week 48. The amount of erm(B) gene in fecal specimens was comparable with the pretreatment level at week 2 but increased at week 8 (0.025) and then returned to the pretreatment level by week 48.ConclusionsHelicobacter pylori eradication with reverse hybrid therapy can lead to shortâ term gut dysbiosis. The amount of erm(B) gene in the stool increased transiently after treatment and returned to the pretreatment level at 1â year postâ treatment.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152555/1/jgh14736_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/152555/2/jgh14736.pd
Equivalent efficacies of reverse hybrid and concomitant therapies in first- line treatment of Helicobacter pylori infection
Background and AimConcomitant therapy is a recommended first- line treatment for Helicobacter pylori infection in most national or international consensuses. Reverse hybrid therapy is a modified 14- day concomitant therapy without clarithromycin and metronidazole in the final 7ĂÂ days. This study aims to test whether 14- day reverse hybrid therapy is non- inferior to 14- day concomitant therapy in the first- line treatment of H.ĂÂ pylori infection.MethodsHelicobacter pylori- infected adult patients were randomly assigned to receive either reverse hybrid therapy (dexlansoprazole 60ĂÂ mg o.d. plus amoxicillin 1ĂÂ g b.d. for 14ĂÂ days, and clarithromycin 500ĂÂ mg plus metronidazole 500ĂÂ mg b.d. for initial 7ĂÂ days) or concomitant therapy (dexlansoprazole 60ĂÂ mg once o.d. plus amoxicillin 1ĂÂ g, clarithromycin 500ĂÂ mg, and metronidazole 500ĂÂ mg b.d. for 14ĂÂ days). H.ĂÂ pylori status was assessed 6ĂÂ weeks after the end of treatment.ResultsHelicobacter pylori- infected participants (nĂÂ =ĂÂ 248) were randomized to receive either 14- day reverse hybrid therapy (nĂÂ =ĂÂ 124) or 14- day concomitant therapy (nĂÂ =ĂÂ 124). Intention- to- treat analysis demonstrated that the two therapies had comparable eradication rate (95.2% vs 93.5%; 95% confidence interval, - 4.0% to 7.4%; PĂÂ =ĂÂ 0.582). However, reverse hybrid therapy had a much lower frequency of adverse events than concomitant therapy (20.2% vs 38.7%, PĂÂ =ĂÂ 0.001). The two therapies exhibited comparable drug adherence (93.5% vs 87.9%, PĂÂ =ĂÂ 0.125).ConclusionsFourteen- day reverse hybrid therapy and 14- day concomitant therapy are equivalent in efficacy for the first- line treatment of H.ĂÂ pylori infection. However, reverse hybrid therapy has fewer adverse events compared with concomitant therapy.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/163472/2/jgh15034_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163472/1/jgh15034.pd
The Efficacy of Endoscopic Papillary Balloon Dilation for Patients with Acute Biliary Pancreatitis
Background. No study investigated the efficacy and safety of endoscopic papillary balloon dilation (EPBD) for the treatment of acute biliary pancreatitis (ABP). Method. We retrospectively reviewed the effects of EPBD on patients with ABP from February 2003 to December 2012. The general data, findings of image studies, details of the procedure, and outcomes after EPBD were analyzed. Result. Total 183 patients (male/female: 110/73) were enrolled. The mean age was 65.9 years. Among them, 155 patients had mild pancreatitis. The meantime from admission to EPBD was 3.3 days. Cholangiogram revealed filling defects inside the common bile duct (CBD) in 149 patients. The mean dilating balloon size was 10.5âmm and mean duration of the dilating procedure was 4.3 minutes. Overall, 124 patients had gross stones retrieved from CBD. Four (2.2%) adverse events and 2 (1.1%) intraprocedure bleeding incidents but no procedure-related mortality were noted. Bilirubin and amylase levels significantly decreased after EPBD. On average, patients resumed oral intake within 1.4 days. The clinical parameters and outcomes were similar in patients with different severity of pancreatitis. Conclusion. EPBD can be effective and safe for the treatment of ABP, even in patients presenting with severe disease
One-way sensitivity analysis results for Strategy 1.
<p>The blue and green bars represent the changes of ICER using upper and lower bound values, respectively, in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0160599#pone.0160599.s001" target="_blank">S1 Table</a>.</p
Flowchart for the four strategies evaluated in this study.
<p>Flowchart for the four strategies evaluated in this study.</p
Numbers of LS probands and relatives and costs for the four strategies.
<p>Numbers of LS probands and relatives and costs for the four strategies.</p
Cost-effectiveness acceptability curves for Strategies 1â4 relative to the Referent strategy.
<p>Cost-effectiveness acceptability curves for Strategies 1â4 relative to the Referent strategy.</p
Human Papillomavirus Infection Is Associated with Decreased Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients: Taiwan Nationwide Matched Cohort Study
Background: Hepatitis C virus (HCV) has been shown to be associated with human papillomavirus (HPV)-positive head and neck cancers. However, studies regarding HPV infection and the risk of new-onset hepatocellular carcinoma (HCC) among chronic hepatitis C (CHC) patients are limited. We examined the risk of HCC in CHC patients with or without HPV infection. Methods: In total, 9905 CHC patients from 2000 to 2016 constituted the whole cohort. HPV was defined as being diagnosed after HCV. The CHC cohort with HPV (N = 1981) and age-, sex-, inception point-, comorbidity-, and medication-matched non-HPV (N = 7924) were followed up until HCC, death, or 2018. HCC patients were extracted from the Taiwan Registry for Catastrophic Illness Database. We adopted the propensity score match and inverse probability of treatment weighting (IPTW) to eliminate bias. Cox proportional hazard regression analyses were performed to calculate HCC risk. Results: After a full adjustment, HPV was not associated with HCC risk (aHR, 0.74; 95% CI, 0.58–0.96 in the main model, and aHR, 0.76; 95% CI, 0.66–0.87 in IPTW, respectively). Almost all subgroup analyses verified this finding (HRs < 1.0). Conclusions: Among CHC patients older than 18 years old, those with HPV infection were associated with a lower risk of subsequent HCC
Sa1159 â The Impacts of On-Demand Versus Continuous Therapy on the Symptom Control and Histological Changes of Metaplastic Esophageal Epithelium in Patients with Barrett Esophagus â a Randomized Controlled Trial
The Frequencies of Gastroesophageal and Extragastroesophageal Symptoms in Patients with Mild Erosive Esophagitis, Severe Erosive Esophagitis, and Barrettâs Esophagus in Taiwan
Background. Gastroesophageal reflux disease (GERD) may present with gastroesophageal and extraesophageal symptoms. Currently, the frequencies of gastroesophageal and extragastroesophageal symptoms in Asian patients with different categories of GERD remain unclear. Aim. To investigate the frequencies of gastroesophageal and extragastroesophageal symptoms in patients with mild erosive esophagitis, severe erosive esophagitis, and Barrettâs esophagus of GERD. Methods. The symptoms of symptomatic subjects with (1) Los Angeles grade A/B erosive esophagitis, (2) Los Angeles grade C/D erosive esophagitis, and (3) Barrettâs esophagus proven by endoscopy were prospectively assessed by a standard questionnaire for gastroesophageal and extragastroesophageal symptoms. The frequencies of the symptoms were compared by Chi-square test. Result. Six hundred and twenty-five patients (LA grade A/B: 534 patients; LA grade C/D: 37 patients; Barrettâs esophagus: 54 patients) were assessed for gastroesophageal and extragastroesophageal symptoms. Patients with Los Angeles grade A/B erosive esophagitis had higher frequencies of symptoms including epigastric pain, epigastric fullness, dysphagia, and throat cleaning than patients with Los Angeles grade C/D erosive esophagitis. Patients with Los Angeles grade A/B erosive esophagitis also had higher frequencies of symptoms including acid regurgitation, epigastric acidity, regurgitation of food, nausea, vomiting, epigastric fullness, dysphagia, foreign body sensation of throat, throat cleaning, and cough than patients with Barrettâs esophagus. Conclusion. The frequencies of some esophageal and extraesophageal symptoms in patients with Los Angeles grade A/B erosive esophagitis were higher than those in patients with Los Angeles grade C/D erosive esophagitis and Barrettâs esophagus. The causes of different symptom profiles in different categories of GERD patients merit further investigations